journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/28071678/multiple-myeloma-in-2016-fresh-perspectives-on-treatment-and-moments-of-clarity
#1
Prashant Kapoor, S Vincent Rajkumar
No abstract text is available yet for this article.
January 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28071677/renal-cell-carcinoma-in-2016-advances-in-treatment-jostling-for-pole-position
#2
Laurence Albiges, Toni K Choueiri
No abstract text is available yet for this article.
January 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031560/the-landscape-of-new-drugs-in-lymphoma
#3
REVIEW
Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens...
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031559/urological-cancer-atezolizumab-an-alternative-to-cisplatin
#4
Peter Sidaway
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031558/lung-cancer-et-platinum-therapy-comes-home
#5
Lisa Hutchinson
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031557/immunotherapy-benefit-with-anti-pd-l1
#6
Diana Romero
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031556/advances-in-the-molecular-genetics-of-gliomas-implications-for-classification-and-therapy
#7
REVIEW
Guido Reifenberger, Hans-Georg Wirsching, Christiane B Knobbe-Thomsen, Michael Weller
Genome-wide molecular-profiling studies have revealed the characteristic genetic alterations and epigenetic profiles associated with different types of gliomas. These molecular characteristics can be used to refine glioma classification, to improve prediction of patient outcomes, and to guide individualized treatment. Thus, the WHO Classification of Tumours of the Central Nervous System was revised in 2016 to incorporate molecular biomarkers - together with classic histological features - in an integrated diagnosis, in order to define distinct glioma entities as precisely as possible...
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28031555/lung-cancer-aura3-magic-reveals-new-standard
#8
Lisa Hutchinson
No abstract text is available yet for this article.
December 29, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27995950/in-the-news-from-ena-2016
#9
Diana Romero
No abstract text is available yet for this article.
December 20, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27995949/surveillance-after-curative-treatment-for-colorectal-cancer
#10
REVIEW
Eric P van der Stok, Manon C W Spaander, Dirk J Grünhagen, Cornelis Verhoef, Ernst J Kuipers
Treatments for colorectal cancer (CRC) of all stages have evolved considerably over the past two decades, resulting in improved long-term outcomes. After curative treatment, however, 30% of patients with stage I-III and up to 65% of patients with stage IV CRC develop recurrent disease. Thus, patients are routinely offered surveillance in order to detect disease recurrence at an early, asymptomatic stage, with the intention of improving survival. Nevertheless, controversy continues to surround the optimal surveillance protocols...
December 20, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27995948/liver-cancer-regorafenib-a-new-resorce-in-hcc
#11
David Killock
No abstract text is available yet for this article.
December 20, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27995947/haematological-cancer-tp53-mutations-sensitize-to-decitabine
#12
Peter Sidaway
No abstract text is available yet for this article.
December 20, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27995946/recist-learning-from-the-past-to-build-the-future
#13
REVIEW
Saskia Litière, Sandra Collette, Elisabeth G E de Vries, Lesley Seymour, Jan Bogaerts
Response Evaluation Criteria In Solid Tumours (RECIST) remain an integral part of the assessment of tumour burden in many clinical trials in oncology; these criteria are used to evaluate the activity and efficacy of new cancer therapeutics in solid tumours. We aim to define the purpose of RECIST, and reflect on the level of documentation needed to enable changes for these criteria to develop a new RECIST. Maintaining the applicability of RECIST as a standard evaluation approach is associated with many challenges, in particular with maintaining a balance between the specificity and generalizability, continued validation and innovation, and use of RECIST in early phase versus late-phase drug development, as well as its relevance in clinical trials versus clinical practice...
December 20, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958298/sarcoma-in-2016-evolving-biological-understanding-and-treatment-of-sarcomas
#14
Jean-Yves Blay, Isabelle Ray-Coquard
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958297/delivering-widespread-brca-testing-and-parp-inhibition-to-patients-with-ovarian-cancer
#15
REVIEW
Angela George, Stan Kaye, Susana Banerjee
The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. Germ line BRCA mutation status is now established as a predictive biomarker of potential benefit from treatment with a PARP inhibitor; therefore, knowledge of the BRCA status of an individual patient with ovarian cancer is essential, in order to guide treatment decisions...
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958296/gynaecological-cancer-parp-inhibition-moving-beyond-brca-mutated-disease
#16
David Killock
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958295/haematological-cancer-rituximab-enhances-responses-to-lenalidomide
#17
Peter Sidaway
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958294/targeted-therapy-sunitinib-modulates-mcl-1-and-mtor-signalling
#18
Peter Sidaway
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958293/small-cell-lung-cancer-in-2016-shining-light-on-novel-targets-and-therapies
#19
Charles M Rudin, John T Poirier
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27958292/imaging-solid-stress-indicates-tumour-pathology
#20
Peter Sidaway
No abstract text is available yet for this article.
December 13, 2016: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"